

## Antineoplastiske og immunmodulerende midler

### Antineoplastic and immunomodulating agents

L01	Antineoplastiske midler Antineoplastic agents
L02	Endokrin terapi Endocrine therapy
L03	Immunstimulerende midler Immunostimulants
L04	Immunsuppressive midler Immunosuppressants

#### Salg pr ATC 3. nivå for gruppe L - Antineoplastiske og immunmodulerende midler

Sales per ATC 3rd level for ATC group L - Antineoplastic and immunomodulating agents

ATC	ATC level name	mill NOK (AUP) <sup>1)</sup>				
		2013	2014	2015	2016	2017
L01A	Alkylating agents	34	34	30	25	26
L01B	Antimetabolites	79	76	82	66	70
L01C	Plant alkaloids and other natural products	54	43	47	46	59
L01D	Cytotoxic antibiotics and related substances	23	24	26	27	31
L01X	Other antineoplastic agents	941	1117	1256	1588	2039
L02A	Hormones and related agents	95	94	96	102	107
L02B	Hormone antagonists and related agents	215	279	295	275	272
L03A	Immunostimulants	341	293	267	239	187
L04A	Immunosuppressants	2259	2637	2817	3050	3377

1) Omfatter kun salg av preparater med markedsføringstillatelse i Norge

## ATC gruppe L

ATC	ATC level name	gram of active ingredient/year				
		2013	2014	2015	2016	2017
<b>L01</b>	<b>Antineoplastiske midler<sup>1)</sup></b>					
<b>L01A</b>	<b>Alkyleringsmidler</b>					
<b>L01AA</b>	<b>Sennepsgassanaloger</b>					
L01AA01	Cyklofosamid	13653	14563	15438	1839	18728
L01AA02	Klorambucil	58	60	67	54	41
L01AA03	Melfalan	188	176	174	153	148
L01AA06	Ifosfamid	11456	10335	9808	11382	10943
L01AA07	Trofosfamid	2463	2013	1725	1680	1668
L01AA09	Bendamustin	407	437	501	556	447
<b>L01AB</b>	<b>Alkylsulfonater</b>					
L01AB01	Busulfan	72	60	57	52	64
L01AB02	Treosulfan			1431	2196	2577
<b>L01AC</b>	<b>Etyleniminer</b>					
L01AC01	Tiotepa		4	9	10	12
<b>L01AD</b>	<b>Nitrosoureaforbindelser</b>					
L01AD01	Karmustin	74	73	94	55	50
L01AD02	Lomustin	98	108	160	156	158
L01AD04	Streptozocin	516	408	183	349	248
<b>L01AX</b>	<b>Andre alkyleringsmidler</b>					
L01AX03	Temozolamid	4715	4130	4876	4205	5181
L01AX04	Dakarbazin	1612	1471	1480	1182	1134
<b>L01B</b>	<b>Antimetabolitter</b>					
<b>L01BA</b>	<b>Folsyreanaloger</b>					
L01BA01	Metotrexat <sup>2)</sup>	5453	5877	5464	6427	8463
L01BA03	Raltitrexed	156		66	80	12
L01BA04	Pemetrexed	1776	1650	1620	1646	1210
<b>L01BB</b>	<b>Purinanaloger</b>					
L01BB02	Merkaptopurin	4993	5233	5963	5904	6181
L01BB03	Thioguanin	119	139	167	142	95
L01BB04	Kladribin	3	3	3	2	3
L01BB05	Fludarabin	108	102	100	97	87
L01BB06	Klofarabin	1	0	1	0	
L01BB07	Nelarabin	17	11	3		8
<b>L01BC</b>	<b>Pyrimidinanaloger</b>					
L01BC01	Cytarabin	9730	8342	8332	9322	8455
L01BC02	Fluorouracil	58562	63755	63594	58829	61987
L01BC05	Gemcitabin	9422	10190	11869	12382	14024
L01BC06	Kapecitabin	207282	206979	220647	223728	215430
L01BC07	Azacitidin	236	341	543	669	811
L01BC08	Decitabin			8	16	33
L01BC52	Fluorouracil, kombinasjoner				1	20
L01BC53	Tegafur, kombinasjoner	36	85	26	30	24
L01BC59	Trifluridin, kombinasjoner					78
<b>L01C</b>	<b>Plantealkaloider og andre naturprodukter</b>					
<b>L01CA</b>	<b>Vincaalkaloider og analoger</b>					
L01CA01	Vinblastin	17	19	22	23	22
L01CA02	Vinkristin	12	12	13	13	13
L01CA03	Vindesin	0,27	0,19	0,19	0,22	0,21
L01CA04	Vinorelbin	579	631	591	578	529
L01CA05	Vinflunin	54	32	47	60	61

1) Inkluderer også salg av preparater uten markedsføringstillatelse i Norge.

2) Metotrexat tablett og ferdigfylte pinner/sprøyter til inj. er klassifisert i L04AX03.

ATC	ATC level name	gram of active ingredient/year				
		2013	2014	2015	2016	2017
<b>L01CB</b>	<b>Podofyllotoksinderivater</b>					
L01CB01	Etoposid	3507	3286	3781	3749	3627
L01CB02	Teniposid	27	15	20	22	22
<b>L01CD</b>	<b>Taxaner</b>					
L01CD01	Paklitaxel	3668	4139	4459	4559	4459
L01CD02	Docetaxel	1032	871	854	898	909
L01CD04	Kabazitaxel	25	16	10	3	10
<b>L01CX</b>	<b>Andre plantealkaloider og naturprodukter</b>					
L01CX01	Trabektedin	0,2	0,2	0,2	0,3	0,3
<b>L01D</b>	<b>Cytotoksiske antibiotika og lignende substanser</b>					
<b>L01DA</b>	<b>Aktinomyciner</b>					
L01DA01	Daktinomycin	0,2	0,3	0,3	0,2	0,2
<b>L01DB</b>	<b>Antracykliner og lignende substanser</b>					
L01DB01	Doxorubicin	481	560	575	601	564
L01DB02	Daunorubicin	52	32	39	52	52
L01DB03	Epirubicin	1222	1265	1289	1315	1127
L01DB06	Idarubicin	6	6	5	6	6
L01DB07	Mitoxantron	6	4	4	5	4
<b>L01DC</b>	<b>Andre cytotoksiske antibiotika</b>					
L01DC01	Bleomycin <sup>1)</sup>	52050	57000	56700	50550	47250
L01DC03	Mitomycin	49	61	55	51	53
<b>L01X</b>	<b>Andre antineoplastiske midler</b>					
<b>L01XA</b>	<b>Platinaforbindelser</b>					
L01XA01	Cisplatin	622	624	644	631	618
L01XA02	Karboplatin	5291	5975	5794	6105	6058
L01XA03	Oxaliplatin	1683	1698	1833	1864	1899
<b>L01XB</b>	<b>Metylhydraziner</b>					
L01XB01	Prokarbazin	438	445	635	663	680
<b>L01XC</b>	<b>Monoklonale antistoffer</b>					
L01XC02	Rituksimab	7696	8948	10579	13305	13552
L01XC03	Trastuzumab	3638	5229	6038	6232	6794
L01XC06	Cetuksimab	535	618	742	1090	1223
L01XC07	Bevacizumab	3112	3583	4078	3902	4030
L01XC08	Panitumumab	622	695	836	838	849
L01XC09	Catumaksomab	0				
L01XC10	Ofatumumab	52	111	34	32	27
L01XC11	Ipilimumab	65	115	101	10	27
L01XC12	Brentuximabvedotin	6	6	6	9	23
L01XC13	Pertuzumab	4	20	360	837	1055
L01XC14	Trastuzumabemtansin		3	6	9	70
L01XC15	Obinutuzumab				14	53
L01XC17	Nivolumab			34	472	1027
L01XC18	Pembrolizumab			8	327	885
L01XC19	Blinatumomab				2	3
L01XC21	Ramucirumab			10	14	34
L01XC24	Daratumumab				28	515

1) Salg angitt i TU (tusen enheter) virkestoff/år. Sales given in TU (thousand units)/year.

## ATC gruppe L

ATC	ATC level name	gram of active ingredient/year				
		2013	2014	2015	2016	2017
<b>L01XD</b>	<b>Aktiverende midler til fotodynamisk- og stråleterapi</b>					
L01XD03	Metylaminolevulinat	1356	1396	1202	1325	1259
L01XD04	Aminolevulinsyre	97	161	140	158	289
<b>L01XE</b>	<b>Proteinkinasehemmere</b>					
L01XE01	Imatinib	54942	56418	55620	62640	62232
L01XE02	Gefitinib	3413	2280	2693	2130	1815
L01XE03	Erlotinib	3862	3749	2831	2868	3227
L01XE04	Sunitinib	1010	1023	1122	1003	848
L01XE05	Sorafenib	7661	7146	5936	6899	4838
L01XE06	Dasatinib	958	1360	1589	1740	2039
L01XE07	Lapatinib	7035	6321	6426	4305	2373
L01XE08	Nilotinib	13188	14700	16890	16940	6475
L01XE09	Temsirolimus	0	1	1	0	0
L01XE10	Everolimus	363	387	435	396	304
L01XE11	Pazopanib	11496	18660	21384	22515	22806
L01XE12	Vandetanib	414	384	405	174	159
L01XE13	Afatinib		145	136	264	294
L01XE14	Bosutinib		101	193	406	274
L01XE15	Vemurafenib	21786	17244	10618	7190	4140
L01XE16	Crizotinib	945	1887	3180	4302	4521
L01XE17	Axitinib	65	67	95	111	68
L01XE18	Ruksolitinib	297	410	585	1010	1404
L01XE21	Regorafenib	27	585	665	595	769
L01XE23	Dabrafenib		2372	4330	5592	6480
L01XE24	Ponatinib		27	48	51	92
L01XE25	Trametinib			0	24	44
L01XE26	Kabozantinib		3	55	249	566
L01XE27	Ibrutinib			5300	10387	14045
L01XE28	Ceritinib			878	1823	2273
L01XE29	Lenvatinib			1	13	15
L01XE31	Nintedanib			1125	5280	9339
L01XE33	Palbociklib			97	1129	6147
L01XE35	Osimertinib					10
L01XE36	Alektinib					1378
L01XE38	Kobimetinib				1	40

ATC	ATC level name	gram of active ingredient/year				
		2013	2014	2015	2016	2017
<b>L01XX</b>	<b>Andre antineoplastiske midler</b>					
L01XX01	Amsakrin	70	76	47	39	61
L01XX02	Asparaginase <sup>1)</sup>	5430	3330	4600	3200	2850
L01XX05	Hydroxykarbamid	372550	405300	432410	453570	475390
L01XX14	Tretinoin	124	207	137	98	178
L01XX17	Topotekan	2	2	2	2	1
L01XX19	Irinotekan	2940	3298	3409	3416	3671
L01XX23	Mitotan	9600	12100	7800	9600	7300
L01XX24	Pegaspargase <sup>1)</sup>	2089	2093	2291	1916	1695
L01XX25	Beksaroten	1035	983	1200	1275	1035
L01XX27	Arsenikk trioksider	1	3	3	4	8
L01XX32	Bortezomib	26	30	28	32	34
L01XX35	Anagrelide	83	91	103	102	104
L01XX41	Eribulin	2	2	2	2	2
L01XX42	Panobinostat			0	9	10
L01XX43	Vismodegib	29	336	269	202	340
L01XX44	Aflibercept	1	2	5		
L01XX45	Karfilzomib				35	105
L01XX46	Olaparib			134	2822	7750
L01XX47	Idelalisib			684	1251	978
L01XX50	Iksazomib					12
L01XX52	Venetoklaks					1

1) Salg angitt i TU (tusen enheter) virkestoff/år./Sales given in TU (thousand units)/year.

## ATC gruppe L

ATC	ATC level name (DDD value)	DDD/1000 inhabitants/year				
		2013	2014	2015	2016	2017
<b>L02</b>	<b>Endokrin terapi<sup>1)</sup></b>	<b>2262</b>	<b>2243</b>	<b>2245</b>	<b>2259</b>	<b>2298</b>
<b>L02A</b>	<b>Hormoner og beslektede substanser</b>	<b>614</b>	<b>597</b>	<b>577</b>	<b>560</b>	<b>554</b>
<b>L02AB</b>	<b>Progestogener</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>6</b>
L02AB01	Megestrol (0,16 g)	6	6	6	6	6
<b>L02AE</b>	<b>Gonadotropinfrigjørende hormonanaloger</b>	<b>608</b>	<b>591</b>	<b>571</b>	<b>554</b>	<b>548</b>
L02AE01	Buserelin (0,11 mg depot implant/1,2 mg N)	10	5	3	2	2
L02AE02	Leuprorelin (0,134 mg depot inj./0,06 mg implant)		262	229	198	172
L02AE03	Goserelin (0,129 mg)	314	324	339	353	373
L02AE04	Triptorelin (0,134 mg)	0	0	0	1	1
L02AE05	Histrelin (0,137 mg)	2				
<b>L02B</b>	<b>Hormonantagonister og beslektede substanser</b>	<b>1648</b>	<b>1646</b>	<b>1668</b>	<b>1699</b>	<b>1744</b>
<b>L02BA</b>	<b>Antiøstrogener</b>	<b>300</b>	<b>280</b>	<b>279</b>	<b>305</b>	<b>333</b>
L02BA01	Tamoxifen (20 mg)	280	258	255	273	288
L02BA03	Fulvestrant (8,3 mg)	20	22	24	32	45
<b>L02BB</b>	<b>Antiandrogener</b>	<b>806</b>	<b>786</b>	<b>765</b>	<b>743</b>	<b>737</b>
L02BB01	Flutamid (0,75 g)	9	7	6	4	4
L02BB03	Bikalutamid (50 mg)	797	766	734	707	694
L02BB04	Enzalutamid (0,16 g)	1	13	25	32	39
<b>L02BG</b>	<b>Enzymhemmere</b>	<b>491</b>	<b>516</b>	<b>556</b>	<b>584</b>	<b>614</b>
L02BG03	Anastrozol (1 mg)	86	71	59	50	41
L02BG04	Letrozol (2,5 mg)	358	396	445	480	521
L02BG06	Eksemestan (25 mg)	47	49	52	54	52
<b>L02BX</b>	<b>Andre hormonantagonister og beslektede substanser</b>	<b>51</b>	<b>64</b>	<b>68</b>	<b>67</b>	<b>60</b>
L02BX02	Degarelix (2,7 mg)	26	34	43	46	44
L02BX03	Abirateron (1g)	25	30	25	21	16
<b>L03</b>	<b>Immunstimulerende midler<sup>1)</sup></b>	<b>315</b>	<b>248</b>	<b>205</b>	<b>200</b>	<b>177</b>
<b>L03A</b>	<b>Immunstimulerende midler<sup>1)</sup></b>	<b>315</b>	<b>248</b>	<b>205</b>	<b>200</b>	<b>177</b>
L03AA02	Filgrastim (0,35 mg)	5	5	4	4	4
L03AA13	Pegfilgrastim (0,3 mg)	37	43	47	55	61
L03AA14	Lipegfilgrastim (0,3 mg)		1,4	9,4	13	5
L03AB01	Naturlig interferon alfa (2 MU)	0,5	0,4	0,4		
L03AB03	Interferon gamma (40 mcg)	0,4	0,7	1,0	1,1	1,0
L03AB04	Interferon alfa-2a (2 MU)	1,3	1,2	0,9	1,2	0,9
L03AB05	Interferon alfa-2b (2 MU)	1,7	1,5	1,4	1,3	1,2
L03AB07	Interferon beta-1a (4,3 mcg)	128	91	66	55	44
L03AB08	Interferon beta-1b (4 MU)	34	25	18	12	9
L03AB10	Peginterferon alfa-2b (7,5 mcg)	14	9	4	3	2
L03AB11	Peginterferon alfa-2a (26 mcg)	18	11	6	7	5
L03AB13	Peginterferon beta-1a (8,9 mcg)		0	0	3	3
L03AX03	BCG vaksine (1,8 mg)	7	7	7	8	8
L03AX13	Glatiramer acetat (20 mg)	68	52	40	36	33
L03AX16	Plerixafor (16,8 mg)	0	0	0	0	0

1) Inkluderer salg av preparater uten markedsføringstillatelse i Norge.

ATC	ATC level name (DDD value)	DDD/1000 inhabitants/year				
		2013	2014	2015	2016	2017
<b>L04</b>	<b>Immunsuppressive midler<sup>1)</sup></b>	<b>3798</b>	<b>4167</b>	<b>4509</b>	<b>4902</b>	<b>5232</b>
<b>L04A</b>	<b>Immunsuppressive midler<sup>1)</sup></b>	<b>3798</b>	<b>4167</b>	<b>4509</b>	<b>4902</b>	<b>5232</b>
<b>L04AA</b>	<b>Selektive immunsuppressive midler</b>	<b>459</b>	<b>533</b>	<b>603</b>	<b>679</b>	<b>716</b>
L04AA04	Antitymocytt immunoglobulin (kanin) (0,1 g)	0,1	0,1	0,1	0,1	0,1
L04AA06	Mycofenolsyre (2 g)	203	210	218	225	233
L04AA10	Sirolimus (3 mg)	10	11	11	12	12
L04AA13	Leflunomid (20 mg)	84	91	98	104	102
L04AA18	Everolimus (1,5 mg)	46	47	48	52	49
L04AA23	Natalizumab (10 mg)	58	58	56	58	58
L04AA24	Abatacept (27 mg)	7	8	10	11	11
L04AA26	Belimumab (0,025 g)	0,7	1,8	2,5	3,1	3,4
L04AA27	Fingolimod (0,5 mg)	48	64	71	79	82
L04AA28	Belatacept (12,5 mg)	0,2	0,2	0,3	0,5	0,8
L04AA29	Tofacitinib					1,4
L04AA31	Teriflunomid (14 mg)	2	33	55	73	78
L04AA32	Apremilast (0,06 g)			0,1	1,1	1,2
L04AA33	Vedolizumab (5,4 mg)		3	15	38	61
L04AA34	Alemtuzumab (0,13 mg)	0,7	6	18	23	22
L04AA37	Baricitinib					0,8
<b>L04AB</b>	<b>Tumornekrosefaktor alfa (TNF-<math>\alpha</math>)-hemmere</b>	<b>1212</b>	<b>1359</b>	<b>1510</b>	<b>1671</b>	<b>1814</b>
L04AB01	Etanercept (7 mg)	325	304	281	279	329
L04AB02	Infliximab (3,75 mg)	444	497	656	801	920
L04AB04	Adalimumab (2,9 mg)	285	295	271	257	256
L04AB05	Certolizumab pegol (14 mg)	56	141	177	214	195
L04AB06	Golimumab (1,66 mg)	102	122	125	120	114
<b>L04AC</b>	<b>Interleukinhemmere</b>	<b>53</b>	<b>79</b>	<b>102</b>	<b>129</b>	<b>173</b>
L04AC01	Daklizumab (5 mg)					0,7
L04AC02	Basiliximab (40 mg)	0,1	0,1	0,1	0,1	0,1
L04AC03	Anakinra (0,1 g)	5	6	7	8	9
L04AC05	Ustekinumab (0,54 mg)	24	44	58	67	69
L04AC07	Tocilizumab (20 mg)	23	28	36	37	41
L04AC08	Kanakinumab (2,7 mg)	0,6	1,0	1,0	1,7	2,4
L04AC10	Secukinumab (10 mg)			0,7	16	51
L04AC11	Siltuksimab (37 mg)				0,0	0,0
<b>L04AD</b>	<b>Kalsineurinhemmere</b>	<b>279</b>	<b>282</b>	<b>291</b>	<b>298</b>	<b>310</b>
L04AD01	Ciklosporin (0,25 g)	140	132	129	125	118
L04AD02	Tacrolimus (5 mg)	139	150	162	173	192
<b>L04AX</b>	<b>Andre immunsuppressive midler</b>	<b>1795</b>	<b>1914</b>	<b>2003</b>	<b>2125</b>	<b>2220</b>
L04AX01	Azatioprin (0,15 g)	299	304	313	320	312
L04AX02	Thalidomid (0,1 g)	8	6	6	4	2
L04AX03	Metotrexat (2,5 mg) <sup>2)</sup>	1478	1590	1665	1772	1865
L04AX04	Lenalidomid (10 mg)	8	10	14	23	33
L04AX05	Pirfenidon (2,4 g)	1,9	2,4	2,9	3,3	3,2
L04AX06	Pomalidomid (3 mg)		1,7	2,0	2,6	4,3

1) Inkluderer salg av preparater uten markedsføringstillatelse i Norge.

2) Omfatter salg av tabletter og ferdigfylte penner/sprøyter til inj. Parenterale preparater brukt i kreftbehandling, se L01BA01.

